Allogene Therapeutics, Inc.
ALLO · XNASCIK 1737287fmd_09KTA4BYXWMBKHANVDD2V881R6Manufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2018 to Sep 30, 2026, 35 periods
| Line item | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Total revenues | – | 0 | 0 | 114 | 0 | 0 | 0 | 0 |
| Rental revenue | – | – | – | – | – | – | 0 | 3 |
| Research and development | 152 | 145 | 193 | 220 | 256 | 243 | 192 | 150 |
| Total operating expenses | 193 | 202 | 258 | 294 | 336 | 328 | 273 | 209 |
| Operating income | (193) | (202) | (258) | (180) | (336) | (328) | (273) | (209) |
| Interest expense | 3 | 0 | 0 | – | – | 0 | 0 | 1 |
| Interest and investment income | – | – | 9 | 2 | 5 | 18 | 20 | 19 |
| Other non-operating income (expense) | (19) | 17 | (58) | (2) | (5) | 0 | 16 | 18 |
| Income before taxes | (212) | (185) | (250) | (257) | – | (327) | (257) | (191) |
| Income tax expense | (0) | (0) | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | (212) | (185) | (250) | (257) | – | (327) | (258) | (191) |
| Net income | (212) | (185) | (316) | (182) | (340) | (327) | (258) | (191) |